Altimmune, Inc. (ALT): debt financing — Altimmune gets $100M Hercules facility, Q1 cash $150M, MASH data expected Q2 2025

Altimmune, Inc.

Up to $100M term loan from Hercules; $15M funded at closing, $25M more in 2025 subject to milestones.
Interest-only for 24 months (extendable to 42); maturity June 1, 2029; no warrants.
Q1 net loss of $19.6M ($0.26 loss per share) vs $24.4M loss in Q1 2024.
Cash, equivalents & short-term investments $150M as of Mar 31, 2025; R&D expense $15.8M.
Top-line IMPACT Phase 2b MASH data expected Q2 2025; Phase 2 AUD/ALD trials expected Q2/Q3 2025.

item 1.01 item 2.02 item 2.03 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Altimmune, Inc. incurred term loan of $15.0 million with Hercules Capital, Inc. at greater of (a) the prime rate as reported in The Wall Street Journal plus 2.45% maturing June 1, 2029.

Instrument: term loan
Principal: $15.0 million
Counterparty: Hercules Capital, Inc.
Rate: greater of (a) the prime rate as reported in The Wall Street Journal plus 2.45%
Maturity: June 1, 2029
Event: incurrence

Exact text from the filing

first Term Loan tranche was made on the Closing Date in an aggregate principal amount of $15.0 million.

View on SEC.gov

73 debt financings filed in the last 30 days. Browse all debt financings →

Altimmune, Inc. filing history →

Source: SEC EDGAR

accession 0001326190-25-000031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.